Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Wilms Tumor 1Unspecified Childhood Solid Tumor, Protocol Specific 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Mesothelioma, Malignant 1Hepatoblastoma 1Adrenocortical Carcinoma 1

Interventions

tazemetostat 3pembrolizumab 1cixutumumab 1Rifampin 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Itraconazole 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × cixutumumab × Other solid neoplasm × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡